FCRL6 Q6DN72

Fc受体样蛋白6 (FcR样蛋白6) (FcRL6) (Fc受体同源物6) (FcRH6) (IFGP6)

功能描述

作为MHC II类受体发挥作用 (PubMed:20519654)。当单独受刺激时，在NK细胞和细胞毒性CD8(+) T细胞的细胞因子产生或细胞毒性颗粒释放中不起作用 (PubMed:17213291, PubMed:18991291)。不作为Fc受体发挥作用 (PubMed:18991291)。 {ECO:0000269|PubMed:17213291, ECO:0000269|PubMed:18991291, ECO:0000269|PubMed:20519654}。

组织特异性

Expressed by cytolytic cells including NK cells, effector and effector-memory CD8(+) T-cells, and a subset of NKT cells (at protein level) (PubMed:17213291, PubMed:18991291, PubMed:20933011). Also expressed in gamma delta T cells and in a rare subset of effector CD4(+) T-cells (at protein level) (PubMed:18991291). Expressed in spleen, skin, peripheral blood leukocytes, liver, lung, bone marrow, small intestine and placenta (PubMed:20933011). Expression among T-cells is greatly expanded in HIV-1 infected individuals, and includes not only effector and effector-memory CD8(+) T-cells but also populations of CD4(+) T-cells (PubMed:17213291, PubMed:20933011). Expression among CD8(+) T-cells and NK cells is expanded in individuals with chronic lymphocytic leukemia (CLL) but is reduced in PBMCs from patients with acute (AML), chronic myeloid leukemia (CML) and non-Hodgkin's lymphoma (PubMed:18991291, PubMed:20933011). Expression is higher in PBMCs and/or CD3(+) cells of patients with autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP) (PubMed:20933011). In contrast, expression in CD3(+) cells from patients with lupus anticoagulans (LA) is higher (PubMed:20933011).

亚细胞定位

Cell membrane